T. Rowe Price Investment Management Inc. Has $33.19 Million Stock Position in Repligen Corporation $RGEN

Key Points

• T. Rowe Price Investment Management Inc. increased its stake in Repligen Corporation by 64.0%, acquiring 101,791 shares to bring their total holdings to 260,848 shares, valued at approximately $33 million.
• Several other institutional investors also boosted their positions in Repligen, with Dimensional Fund Advisors LP increasing their stake by 28.0% and Tower Research Capital LLC TRC by 89.2% in the last quarter.
• Despite a missed earnings estimate for the quarter, Repligen's revenue rose 14.8% compared to the previous year, prompting analyst ratings to reflect a consensus of "Moderate Buy" with an average price target of $169.45.

T. Rowe Price Investment Management Inc. boosted its holdings in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 64.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 260,848 shares of the biotechnology company's stock after purchasing an additional 101,791 shares during the period. T. Rowe Price Investment Management Inc. owned approximately 0.46% of Repligen worth $33,191,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in RGEN. Raiffeisen Bank International AG acquired a new stake in Repligen during the fourth quarter valued at approximately $29,000. Itau Unibanco Holding S.A. acquired a new stake in Repligen during the fourth quarter valued at approximately $40,000. Signaturefd LLC lifted its stake in Repligen by 65.3% during the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 128 shares during the last quarter. Center for Financial Planning Inc. lifted its stake in Repligen by 110.3% during the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock valued at $47,000 after purchasing an additional 193 shares during the last quarter. Finally, UMB Bank n.a. lifted its stake in Repligen by 99.4% during the first quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 332 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Repligen news, Director Martin D. Madaus purchased 1,800 shares of the company's stock in a transaction dated Friday, August 8th. The shares were bought at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the purchase, the director directly owned 1,800 shares in the company, valued at $201,834. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.20% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Barclays assumed coverage on shares of Repligen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $150.00 target price for the company. Stephens upgraded shares of Repligen to an "overweight" rating and set a $160.00 price target on the stock in a report on Tuesday, July 22nd. HC Wainwright restated a "buy" rating and set a $180.00 price target on shares of Repligen in a report on Monday, May 5th. Evercore ISI cut their price target on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a report on Tuesday, July 8th. Finally, Royal Bank Of Canada boosted their price target on shares of Repligen from $193.00 to $204.00 and gave the company an "outperform" rating in a report on Wednesday, July 30th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $169.45.

Repligen Stock Up 0.6%

Repligen stock traded up $0.72 during trading hours on Friday, hitting $122.89. The company had a trading volume of 153,098 shares, compared to its average volume of 772,813. The firm has a market capitalization of $6.91 billion, a P/E ratio of -491.48, a price-to-earnings-growth ratio of 2.19 and a beta of 1.05. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The firm's fifty day moving average is $121.67 and its 200-day moving average is $130.50. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.03). The company had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The firm's quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.40 EPS. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, research analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.